News | July 25, 2007

FDA Gives Green Light to St. Jude’s Embolic Protection System, Flow Control Device

July 26, 2007 - St. Jude Medical Inc. announced that the FDA has granted clearance for the 7F Proxis Embolic Protection System, a system designed to extract debris that may become dislodged when an intervention, such as delivering a stent, is performed on patients who have previously undergone a heart bypass procedure using a saphenous vein graft (SVG).

The Proxis Embolic Protection System provides protection proximally, or "upstream," from an SVG blockage. As stenting may dislodge debris that flows downstream, thus increasing the risk of heart attack, stroke or other complications, the embolic protection system is engineered to extract dislodged debris. Additionally, the Proxis Embolic Protection System allows cardiologists to remove dislodged debris floating in the bloodstream.
The system includes an inflation device and a catheter with a vessel-sealing balloon. Cardiologists inflate the sealing balloon upstream to the lesion and temporarily suspend blood flow before delivering the interventional device to the diseased area. Once the intervention is complete, fluid and debris are aspirated from the vessel.
In a related story, the FDA cleared St. Jude Medical for its 6F Proxis Flow Control System, a smaller device for controlling the flow of fluids in the coronary and peripheral vasculature by temporarily suspending blood flow within a vessel. This technique assists clinicians in visualizing the lesion or delivering other therapies.

For more information:

Related Content

The Boston Scientific FilterWire EZ embolic protec filter system.

The Boston Scientific FilterWire EZ embolic protection system.

News | Embolic Protection Devices| October 31, 2017
October 31, 2017 — The VAMPIRE 3 study evaluated if the selective use of distal filter protection might decrease the
Claret Medical Closes $14.5 Million in Series C Financing for Sentinel Cerebral Protection System
News | Embolic Protection Devices| October 23, 2017
October 23, 2017 — Claret Medical announced that it has closed on a Series C financing of $14.5 million led by Lights
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Protembis Announces Successful First-in-Human Use of  ProtEmbo Cerebral Protection System in European Trial
News | Embolic Protection Devices| September 07, 2017
Protembis GmbH announced the first clinical applications of its ProtEmbo Cerebral Protection System to complement a...
PinnacleHealth First in Pennsylvania to Implant Sentinel Cerebral Protection System
News | Embolic Protection Devices| August 23, 2017
PinnacleHealth is the first hospital in Pennsylvania and one of the first 10 in the country to introduce new technology...
PinnacleHealth Initiates Clinical Study of TriGuard Embolic Protection Device
News | Embolic Protection Devices| April 11, 2017
Through a new clinical trial, patients at Harrisburg, Pa.-based PinnacleHealth have access to an investigational device...
Cardiogard embolic protection system for surgical valve reaplacement

The CardioGard embolic protection system for surgical aortic valve replacement.

Feature | Embolic Protection Devices| March 22, 2017
March 22, 2017 — Two U.S.
Keystone Heart, TriGuard Embolic Protection Device, real-world results, PCR London Valves Conference 2016
News | Embolic Protection Devices| September 29, 2016
Keystone Heart Ltd. recently announced the safety and efficacy of the TriGuard Cerebral Embolic Protection device...
Claret Medical, Sentinal CPS, cerebral protection system, FDA marketing application, TAVR, embolic protection
News | Embolic Protection Devices| September 20, 2016
Claret Medical announced its filing of a marketing application with the U.S. Food and Drug Administration (FDA) for...
InspireMD, CGuard, PARADIGM study, EuroPCR 2015, Musialek

Image courtesy of InspireMD

News | Embolic Protection Devices| June 23, 2015
InspireMD Inc. announced that its CGuard embolic prevention system reported positive results in the PARADIGM study at...
Overlay Init